Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
On August 12, 2026, Eli Lilly filed six lawsuits against businesses it alleges are illegally selling retatrutide — its experimental weight-loss drug, still in Phase 3 trials and approved by no regulator anywhere. Beyond the courtroom, Lilly says it is urging credit card companies, payment processors, and e-commerce platforms to end support for illicit retatrutide sellers. For the research-peptide market, where retatrutide has become the most-discussed compound, this is the most consequential enforcement action since the Paradigm prosecution — and its legal theory reaches further than the defendant list.
Facts below are drawn from public court filings and national news coverage, August 12, 2026. None of the six defendants is a vendor covered on this site.
The six suits target a cross-section of the market — online research-peptide sellers, a compounding pharmacy, and medical-spa businesses — rather than one business model:
The Lone Star Peptide case (S.D. Tex., 4:26-cv-06562) is the filing whose details have circulated most widely, because of the argument it makes — covered below.
The defendants weren't caught without disclaimers. Public filings describe sites carrying the full research-only apparatus — in vitro only, not for human or animal use, not FDA approved. Lilly's complaints go around the disclaimers rather than through them: they point to what else the sites published. A peptide dosage calculator. A titration schedule with stepped weekly holds. A reconstitution walkthrough. The argument is that a business genuinely serving in-vitro researchers has no use for tools that tell a person which line to draw a syringe to — so the site's own features contradict its label.
Whether courts adopt that reasoning will play out in litigation, and this page will be updated as the dockets move. What's already true: the theory is now public, every vendor in this market has read it, and the era when a disclaimer paragraph was treated as a force field is visibly closing. The same week these suits landed, the Paradigm sentencing showed the criminal version of the same lesson — the owner's forged certificates mattered more than his labels.
Payment disruptions can arrive before legal outcomes. Lilly's pressure on processors and platforms means a vendor's checkout can stop working long before any court rules — abruptly, and without the vendor announcing why. Orders in flight during a processor cutoff are the practical risk to watch.
Sudden closures have a pattern here. This market's history — which we document on the closures tracker — is that pressured vendors wind down fast, sometimes with unshipped orders and successor scams appearing within weeks. Enforcement waves accelerate that cycle.
The named six are unlikely to be the end. Enforcement attention historically spreads from named defendants toward lookalike operations. None of the six is a vendor covered on this site; our monthly review re-checks every covered vendor's status, and this page will be updated as the cases develop.
2026's enforcement wave — criminal, civil, and regulatory in the same summer — keeps validating one idea: vendors whose claims can be verified outside their own websites are the ones that survive scrutiny. That is the exact standard our scoreboard scores, and our COA guide teaches the checks.
On August 12, 2026, Lilly filed six lawsuits against Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide — a mix of online research-peptide sellers, a compounding pharmacy, and med-spa businesses that Lilly alleges sold illegal versions of retatrutide. The filings are public court records; the Lone Star case, for example, was filed in the Southern District of Texas.
Retatrutide is an investigational compound in Phase 3 clinical trials for obesity and related conditions. No regulator anywhere has approved it for human use, which is the foundation of Lilly's claims against sellers marketing it to consumers. Research-use-only sales occupy a legal gray zone that these suits — and the FDA warning letters that preceded them — are actively contesting.
The most notable feature of the public complaints is that disclaimers alone didn't deter the filings. In the Lone Star complaint, Lilly points to the seller's own site apparatus — a dosage calculator, a titration schedule, a reconstitution walkthrough — as evidence that the products were intended for human use regardless of the research-only labeling. Whether courts accept that theory will be decided in litigation; the argument itself is now on the public record, and every vendor in this market is aware of it.
Three practical effects are worth watching regardless of how the suits resolve. First, Lilly says it is pressing credit card companies, payment processors, and e-commerce platforms to stop supporting illicit retatrutide sellers — payment disruptions can hit vendors abruptly and without notice. Second, sued or pressured vendors can wind down quickly; the research-peptide market already has a pattern of sudden closures, which we track. Third, enforcement attention tends to spread from the named defendants to lookalike operations. None of the six defendants is a vendor covered on this site, and we monitor our covered vendors' status monthly.
They are separate actions with a shared climate. Paradigm was a federal criminal prosecution — its owner was sentenced to nearly six years in August 2026 after admitting the company forged laboratory certificates and sold adulterated products. The Lilly suits are civil actions by a drug maker protecting an investigational product. Together with the FDA's July advisory-committee votes on peptide compounding, they mark 2026 as the year enforcement arrived in this market from three directions at once: criminal, civil, and regulatory.
The same way our verification rubric evaluates vendors, because enforcement risk and quality risk share the same tells: prefer vendors whose certificates can be verified at a named laboratory rather than only on the vendor's site, whose claims stay consistent across their own pages, and whose independent review base is checkable. The Paradigm case established that forged certificates happen; our guide to reading a COA covers how to catch the patterns, and the scoreboard applies those checks vendor by vendor.